![null](https://www.adial.com/wp-content/uploads/2021/12/AboutUs.jpg)
About > Company
The Adial Vision
To build the world’s leading pharmaceutical company focused on improving the quality of life of patients by preventing and treating addiction and other unmet medical needs.
![null](https://www.adial.com/wp-content/uploads/2021/11/Cary-Claiborne-494x494-BG-2.png)
Adial is at an important inflection point with our many recent accomplishments. Addiction is a devastating disease that takes an enormous toll on our families, communities, country and the economy. I am excited to lead Adial as we advance our mission to bring life-transforming therapies to patients who are in need. This begins with our lead investigational drug candidate, AD04, a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder and other addictions.
Cary J. Claiborne Chief Executive Officer
The Adial Story
![null](https://www.adial.com/wp-content/uploads/2021/12/video-08.jpg)
Adial History
Adial Pharmaceuticals was founded in 2010, following pioneering research into the genetics of addiction that began in the 1990s. The research focused on the potential of a serotonin-3 blocker to aid individuals with certain genetic markers related to the serotonin system. This hypothesis was tested through animal studies, imaging studies, and early clinical work, culminating in a Phase 2 study conducted by the University of Virginia at multiple sites. The successful outcomes of these studies led to the formation of Adial.
Adial Timeline
-
2010–2011
Adial Founded
Licenses AD04 from the University of Virginia
-
2014
USPTO grants 1st U.S. patent for AD04 for the treatment of Alcohol Use Disorder (AUD) in genetically targeted patients
-
2018
Adial Pharmaceuticals listed on U.S. NASDAQ
(Ticker: ADIL) -
2020
ONWARD Phase 3
ADO4 Onward Phase 3 Trials begin
-
2022
ONWARD Phase 3 Trials completed
ONWARD Phase 3 Trial results announced